Only two medications are FDA-approved for PTSD. Neither works reliably. As PTSD claims expand across workers’ compensation, the gap between what clinicians have and what injured workers need has never been more visible and the emerging treatments that might close that gap are not yet ready for routine use.
June is PTSD Awareness Month, and it arrives at a moment of genuine complexity for pharmacy and medical management professionals in workers’ compensation. PTSD claims are becoming more common, more compensable under evolving state legislation, and more pharmacologically complicated, particularly when PTSD co-occurs with the physical injuries and chronic pain conditions that dominate the workers’ comp landscape. Understanding what the evidence actually supports, where standard pharmacotherapy falls short, and what is emerging on the horizon is important.
The Narrow Evidence Base for PTSD Pharmacotherapy
Despite the clinical complexity of PTSD and the range of symptoms it produces, the FDA-approved pharmacological landscape is narrow. Sertraline (Zoloft) and paroxetine (Paxil), both selective serotonin reuptake inhibitors (SSRIs), are the only medications the FDA has approved for PTSD.[1] The 2023 VA/DoD Clinical Practice Guideline identifies these two agents, along with the SNRI venlafaxine, as having the most robust evidence for symptom reduction in randomized controlled trials.[2]
The effect sizes are modest. Sertraline demonstrates a response rate of approximately 53% in reducing PTSD symptoms compared to placebo; paroxetine approximately 62%.[3] In combat-related PTSD specifically, SSRIs have shown limited effectiveness; a distinction relevant in workers’ comp claims involving occupational trauma among first responders, military contractors and corrections personnel. Both agents carry side effect profiles that include nausea, sexual dysfunction, and in the case of paroxetine, a clinically significant discontinuation syndrome.
The VA/DoD guideline is clear on one point: trauma-focused psychotherapy is the first-line treatment for PTSD. Pharmacotherapy is reserved for situations where psychotherapy is unavailable, declined, or insufficient.[2] Medications are best understood as adjunctive to behavioral intervention, not standalone solutions. In workers’ comp claims where access to trauma-focused therapy may be limited or delayed, this distinction has direct implications for how pharmacy spend is authorized and monitored.
The Polypharmacy Risk in PTSD Claims
PTSD rarely presents in isolation. In workers’ comp, it commonly co-occurs with chronic pain, sleep disorders, depression, anxiety, and substance use; each of which may generate its own prescription. The trajectory toward polypharmacy in PTSD claims follows a familiar pattern: each symptom cluster attracts a prescriber, each prescriber adds a medication, and the cumulative pharmacological burden becomes a barrier to the recovery it was intended to support.
PTSD claims that include concurrent opioid therapy for physical injuries present particularly elevated risk. Opioids can blunt the emotional processing that trauma-focused therapies depend on, may worsen hyperarousal symptoms, and introduce central nervous system (CNS) depressant interactions when combined with sedating psychiatric medications. Benzodiazepines warrant specific attention: they are not recommended by major guidelines for PTSD. Benzodiazepines use may interfere with fear extinction learning, the neurological mechanism that trauma-focused therapy works through, yet they are frequently prescribed for comorbid anxiety or sleep symptoms in this population.[4] The result is a pharmacological burden that can mimic or worsen the cognitive and functional deficits that define PTSD itself, complicating both impairment assessment and return-to-work determination.
For pharmacy benefit managers and claims professionals, the red flags in a PTSD claim parallel those in complex TBI or spinal cord injury claims:
- Benzodiazepines co-prescribed with opioids in a PTSD claim, creating layered CNS depression with limited therapeutic justification
- Multiple sedating CNS-active agents without documented rationale or coordinating provider
- Escalating medication regimens without corresponding functional improvement or documented therapeutic goals
- Prescribing fragmented across multiple specialists with no single provider owning the complete medication regimen
Psychedelic-Assisted Therapy: Promising Evidence, Unresolved Regulatory Status
No discussion of the PTSD treatment landscape in 2026 would be complete without addressing psychedelic-assisted therapies. And no responsible discussion of them in the workers’ comp context can begin without a clear statement: these treatments are not approved for routine clinical use in the United States. Workers’ comp payers are not obligated to cover them, and no state workers’ comp system has a framework for authorizing them.
MDMA (3,4-methylenedioxymethamphetamine)-assisted therapy received FDA Breakthrough Therapy designation in 2017 for treatment-resistant PTSD, signaling the agency’s recognition that preliminary evidence was promising enough to warrant expedited development.[4] Phase 3 trials reported that more than 70% of participants receiving MDMA combined with structured psychotherapy no longer met diagnostic criteria for PTSD at follow-up. This is a clinically meaningful result in a population that had not responded adequately to existing treatments.[5]
In August 2024, the FDA declined to approve the Lykos Therapeutics NDA for MDMA-assisted therapy, requesting an additional Phase 3 trial. The agency cited concerns about study design, ineffective blinding due to MDMA’s psychoactive effects, data integrity questions related to investigator misconduct at one trial site, and the absence of key safety data.[6] The FDA’s concerns are legitimate scientific questions, not bureaucratic overcaution. The honest assessment is that the evidence is genuinely promising and genuinely incomplete.
Research continues. Multiple VA- and DoD-funded studies initiated in 2025 are currently underway, representing the VA’s first formal investigation of psychedelic-assisted therapy in veterans with PTSD. The Department of Defense has separately allocated $4.9 million to investigate psychedelics for PTSD treatment.[7] Psilocybin, which carries FDA Breakthrough Therapy designation for treatment-resistant depression, is also under active investigation for trauma-related conditions, though it is even further from regulatory approval for PTSD than MDMA.
For workers’ comp stakeholders, one legislative development is worth noting: Arizona enacted a law in 2024 allowing firefighters and peace officers with PTSD to receive workers’ comp coverage for MDMA-assisted therapy contingent on federal approval.[8] It is a forward-looking placeholder, not an active coverage mandate, but it signals that some state legislatures are already positioning for the eventual regulatory resolution of these therapies.
The practical questions to be asking now, even without immediate clinical applicability:
- If MDMA-assisted therapy eventually receives FDA approval, how will workers’ comp payers evaluate compensability and medical necessity? Having an analytical framework ready matters.
- Standard SSRI therapy fails a substantial proportion of PTSD patients. In a claims population with treatment-resistant PTSD, understanding the emerging evidence landscape is part of being a knowledgeable clinical partner.
- Psychedelic-assisted therapy as currently studied requires structured clinical settings, trained therapists, and multiple treatment sessions representing a model that is fundamentally different from a prescription, with different authorizations and oversight requirements.
A Relationship-Focused Approach
PTSD in workers’ comp is not primarily a pharmacy concern. It is a whole-person recovery problem that intersects with pharmacy management in ways that can either support or undermine an injured worker’s trajectory. The medications prescribed matter and so does the coordination, the monitoring and the clinical oversight that helps to ensure those medications are serving a defined purpose rather than accumulating without accountability.
At Preferred Medical, our role in PTSD claims is to support claims professionals with current clinical intelligence: flagging polypharmacy risk, identifying evidence-inconsistent prescribing patterns, and providing clear information about a treatment landscape that is evolving faster than most workers’ comp formulary policies can track. Psychedelic-assisted therapies may represent a meaningful advance for a population that current pharmacotherapy fails too often. But meaningful advances require rigorous evidence, and rigorous evidence takes time.
For now, the most important intervention we can offer injured workers with PTSD is the same one that benefits all complex claims: ensuring that every medication on their regimen is there for a reason, serving a measurable goal, and being actively reassessed as recovery (or the absence of it) becomes clearer.
References
1. American Psychological Association. (2023). Medications for PTSD. Retrieved from https://www.apa.org/ptsd-guideline/treatments/medications
2. U.S. Department of Veterans Affairs. (2023). VA/DoD clinical practice guideline for the management of posttraumatic stress disorder and acute stress disorder (Version 4.0). Department of Veterans Affairs and Department of Defense.
3. Szafranski, D. D., Stabb, S. D., Litz, B. T., & Martin, A. M. (2025). Pharmacotherapy for post-traumatic stress disorder: Systematic review and meta-analysis. Therapeutic Advances in Psychopharmacology, 15. https://doi.org/10.1177/20451253251321048
4. U.S. Department of Veterans Affairs, National Center for PTSD. (2025). Clinician’s guide to medications for PTSD. Retrieved from https://www.ptsd.va.gov/professional/treat/txessentials/clinician_guide_meds.asp
5. Howland, R. H. (2025). Psychedelic-assisted therapy: An overview for the internist. Cleveland Clinic Journal of Medicine, 92(3), 171–181.
6. Mitchell, J. M., Ot’alora, G. M., van der Kolk, B., Shannon, S., Bogenschutz, M., Gelfand, Y., et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: A randomized, placebo-controlled phase 3 trial. Nature Medicine, 29, 2473–2480. https://doi.org/10.1038/s41591-023-02565-4
7. Lykos Therapeutics. (2024, August). Statement on FDA complete response letter for MDMA-assisted therapy NDA. Lykos Therapeutics.
8. Lindus Health. (2025, July 22). Psychedelics in clinical trials: A promising frontier in mental health treatment. Retrieved from https://www.lindushealth.com/blog/psychedelics-in-clinical-trials-a-promising-frontier-in-mental-health-treatment
9. Arizona Governor’s Office. (2024). SB 1054: Workers’ compensation coverage for MDMA therapy for first responders [contingent on federal approval]. State of Arizona.